New immune therapy for chronic hepatitis B slashes virus levels in trial
Developer says VRON-0200 shows potential to improve 'functional cure' rates
Written by |
One-time treatment with VRON-0200 reduced hepatitis B virus (HBV) levels in the blood of most people with chronic hepatitis B — early trial findings that suggest the experimental immune-modulating therapy may be effective for patients globally.
That’s according to data from a small clinical study that tested VRON-0200’s safety and early efficacy in patients with chronic hepatitis B infection.
Virion Therapeutics, the therapy’s developer, shared these findings in a poster at the 33rd Conference on Retroviruses and Opportunistic Infections, held Feb. 23-25 in Denver. The poster was titled “VRON-0200 Induced Broad and Sustained Anti-HBV Immunity in Chronically HBV-Infected Patients.”
“VRON-0200 is the first new HBV immune modulator since pegylated interferon to show durable clinical activity with sustained and/or improving anti-HBV responses up to one year (360 days) following a single dose,” Sue Currie, PhD, chief operating officer at Virion and coauthor of the poster, said in a company press release detailing the findings. Pegylated interferon is an approved immune-modulating therapy for hepatitis B.
Currie said the data show that VRON-0200 “has the potential to prevent the need for rescue medications after HBV treatment discontinuation, and [to] improve overall functional cure rates” in chronic hepatitis B. A functional cure means HBV, which causes hepatitis B, is suppressed to a level where antiviral treatments can be discontinued.
HBV is spread by contact with bodily fluids and infects the liver, leading to liver inflammation or hepatitis. In some patients, especially those infected early in life, HBV can result in a chronic infection that can set the stage for life-threatening complications such as liver cancer.
VRON-0200 part of new ‘spark-and-fan’ treatment strategy
VRON-0200, administered via a single injection into the muscle, is an experimental therapy designed to trigger immune cells to more effectively attack HBV. It is being developed as part of a so-called spark-and-fan treatment strategy. The idea is that a one-time treatment with VRON-0200 acts as a spark, initiating an anti-HBV immune response that helps bring down viral levels.
After that, other hepatitis B treatments can be given to fan the flames, further suppressing virus levels to achieve a functional cure.
“VRON-0200 … with its favorable safety and tolerability profile, documented durable clinical activity, and convenient single [into muscle] administration, along with its potential for increased accessibility due to its ease of [scalability] and distribution, make it ideal for global public health initiatives,” said Andrew Luber, CEO of Virion and coauthor of the poster.
Currie added that the spark-and-fan approach “could make VRON-0200 a foundational backbone agent to a wide range of future Functional Cure strategies.”
VRON-0200 … with its favorable safety and tolerability profile, documented durable clinical activity, and convenient single [into muscle] administration, … make it ideal for global public health initiatives [in treating chronic hepatitis B].
The Virson-sponsored Phase 1b clinical trial (NCT06070051), which began enrolling its final patient group last month, is evaluating the safety and preliminary effectiveness of VRON-0200 in adults with chronic hepatitis B.
Early trial testing therapy in people with chronic hepatitis B
The new presentation covers outcomes from 35 participants. The researchers specifically looked at how VRON-0200 treatment affected blood levels of HBsAg, a protein critical for HBV’s ability to infect cells and evade the immune system. It is used as a proxy for viral load.
Eight of the participants received an injection of VRON-0200 followed by treatment with elebsiran and tobevibart, two experimental antiviral therapies being developed by Virion for chronic hepatitis B.
All seven evaluable patients experienced “rapid and profound HBsAg declines” within a week of starting antiviral treatment, the researchers wrote. In three patients, HBsAg levels fell so low that the virus could no longer be detected with standard lab tests.
The scientists noted that these beneficial effects were sustained for the duration of the antiviral treatment — about 5.5 months — and continued for one month after the last dose of antiviral treatment.
“The rapid HBsAg declines seen when combined with investigational antivirals, the ‘fan’ to the VRON-0200 ‘spark’, has the added future potential of shortening combination treatment regimens, and also expansion to other populations,” Currie said, noting that this approach may also help treat other types of viral infection.
The other 27 trial participants were given one or two injections of VRON-0200 without additional experimental antivirals. Reductions in HBsAg levels were detected after about one month and were sustained and/or deepened up to one year in all but four patients. Outcomes were generally similar among patients given one or two injections of VRON-0200.
Across all 35 patients, VRON-0200 was generally well tolerated, with no treatment-related adverse events reported.
Virion is now planning a new Phase 2b clinical trial, dubbed SPARK-B, to further explore VRON-0200 as a potential hepatitis B treatment.
“A Phase 2b SPARK-B trial for HBV Functional Cure is in development and will use the ‘Spark and Fan’ approach to evaluate VRON-0200 in combination with investigational antivirals,” Luber said.
Yi Rang Kim
Dear ,
Cooperation with your company for the sale of HBV 'Functional Treatment' antibodies and the manufacturing of edible vaccines.
Proposal for the Sale of National Priority Antibodies and Cooperation for the Cure of Viral Diseases .
Eliminating human and animal viral infection antigens leads to the loss of immune cells resulting from the constant battle between the antigen virus and the individual's immune cells.
Research on eliminating human and animal viral antigens using chemicals is a waste of time.
The decisive factor in curing human and animal viral antigen infections lies solely in the activation of autoimmune cells.
We must not forget the fact that no chemical method on Earth can restore or maintain human and animal immune cells to normal levels.
We may send you samples of the edible vaccine at your discretion.
Please verify toxicity testing, tests for harmlessness to the human body and suitability, and audits of your company's standards.
Subsequently, after oral ingestion by patients ( HBV, HIV, HBV + HIV CO - infection ),
Changes in HBV patients' virus levels before and after ingestion.
Changes in HIV patients' immune cells before and after ingestion.
This process will prove the efficacy of the edible vaccine.
We inform you that edible vaccine production can be manufactured and supplied in your country, at a designated location in your country, or at our headquarters.
Removing viral infection antigens from humans and animals results in the loss of immune cells due to the continuous battle between the antigenic virus and the individual's immune cells.
Research using chemicals to remove viral antigens from humans and animals is a waste of time.
We must not forget the fact that no chemical method on Earth can restore or maintain human and animal immune cells to normal levels.
When ingested orally by infected humans and animals, the edible vaccine demonstrates excellent therapeutic effects in eradicating infectious viruses. The path to HBV antigen elimination is to completely eradicate the infected virus by reinforcing lost immune cells and maintaining normal levels. Through the antigen elimination function, an individual's immune cells are restored to maintain health.
Number of normal immune cells in the human body.
CD-4+ T lymphocytes and CD-8+ cells: 500–1600 / mm³
Platelet count: 140,000–450,000 / mm³
When infected with a virus, countless immune cells are sacrificed, and immune cell loss continues during the ceaseless battle.
Actual CD-4 and CD-8 levels are 200–300 / mm³.
Platelet count: 10,000–20,000 / mm³
Due to these figures, daily life becomes very difficult.
The only way to replenish immune cells lost in the fight against the infectious virus is to consume edible vaccines based on medicinal plants.
Requests from research institutions studying the clinical results of therapeutic vaccines support the feasibility of developing vaccines using attenuated live immune cells.
Before administering the edible vaccine, viral antigens are eliminated to verify current viral replication and proliferation levels. (1) JPG.
The viral clearance rate indicates the viral antigen clearance rate 3 months after administering the edible vaccine. (2) JPG.
These are the antibody levels after viral antigens have been completely eliminated by administering the edible vaccine orally once daily for 5 months. (3) JPG.
The regeneration and normalization of immune cells necessary for the eradication of infectious viruses is the only food-based treatment that only God can oversee.
This involves eradicating infectious antigens using an orally ingested edible vaccine,
and this is an example of immune cell enhancement under God's control.
The precise mechanism of Hepatitis B treatment.
One may experience various symptoms such as hepatitis, liver cirrhosis, jaundice, cerebral fibrosis, ascites, and pain caused by ruptured varices.
Ingesting edible vaccines leads to the alleviation of severe symptoms and the path to a complete cure.
Among human viral antigens, the Hepatitis B virus (HBV) is the most difficult to treat. (Complete elimination of protein antigens: HBsAg, HBcAg, HBeAg, and complex antigens)
The world's first "natural medicinal plant extract" provides the basis for precise "immunological conversion" therapy that eliminates Hepatitis B virus antigens. (Hospital Test Record)
Test Name-----------------------------Test Result---------------------------Reference Value----------------------------------- Unit
HBsAg ----------------------------------Neg (<0.05) ------------------------------Neg <0.05 --------------------------------------IU/mL
Anti-HBc -------------------------------Pos ----------------------------------------11.64 ------------------------------------------mIU/mL
Anti-HBs ------------------------------- Pos ---------------------------------------- 11.8 ------------------------------------------ mIU/mL
There is no record of confirming figures like the above anywhere in the world; this is the first global confirmation by this laboratory.
This project is a guide to the world's valuable medicinal plant resources that provides answers to the mechanisms of viral antigen eradication for human infectious diseases, which modern medicine and science have yet to solve.
The "processable and edible medicinal plants" mentioned here grow naturally in Korea, North Korea, North and South America, Australia, New Zealand, Russia, India, the Middle East, Egypt, Africa, China, Vietnam, Cambodia, and South America.
These plants grow naturally.
The consumption of edible vaccines does not affect food, tea, contaminated food and medicines, nutritional supplements, natural foods, vitamins, favorite foods, injections, drugs, contaminated air and water, diet, or lifestyle, and they never conflict with one another.
We promote cooperation for the universal application of various formulations, including CAR-T, cell therapy, and mRNA vaccines.
The development of novel mDNA antibodies capable of eradicating unmet viral antigens through joint research is a global achievement.
Because mRNA can be synthesized rapidly and in large quantities in a cell-free system through the in vitro transcription of DNA templates, the development of therapeutic vaccines is possible in just a few weeks.
Duration of Administration for Edible Vaccine Treatments for Human Infectious Virus Antigen Removal:
For the edible vaccine designed to eradicate Hepatitis B virus (HBV) antigens, the antigens are automatically eliminated after 6 to 8 months of oral administration.
For the oral vaccine designed to block HIV antigen mutations, the antigens are automatically eliminated after 3 to 5 months of oral administration.
This 100% natural substance has been proven harmless to the human body, even if just a single drop comes into contact with the eyes of the manufacturer of this edible vaccine made from pure natural ingredients.
Warmest regards,
Yi Rang Kim
Senior Researcher / Representative Staff
Virus Antigen Eradication Research